chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test, Vaccination failure
Clinical narrative: Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a Consumer or other non HCP.  A 50-year-old female patient (not pregnant) received BNT162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), on 11Dec2023 at 13:45 as dose 1, single (Batch/Lot number: unknown) at the age of 50 years, in left arm for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (DOSE 1, MANUFACTURER UNKNOWN), for COVID-19 immunisation; Covid-19 vaccine (DOSE 2, MANUFACTURER UNKNOWN), for COVID-19 immunisation; Covid-19 vaccine (DOSE 3 (BOOSTER), MANUFACTURER UNKNOWN), for COVID-19 immunisation. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset Dec2023, outcome "recovered" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (24Dec2023) negative; (25Dec2023) negative; (26Dec2023) negative. Therapeutic measures were taken as a result of vaccination failure, covid-19 which included paxlovid from 20Dec2023 to 24Dec2023.  The information on the batch/lot number for BNT162b2 omi xbb.1.5 will be requested and submitted if and when received.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test, Vaccination failure
Clinical narrative: COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a Consumer or other non HCP.  A 59-year-old female patient (not pregnant) received BNT162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), on 04Oct2023 at 17:00 as dose 1, single (Lot number: HH7595) at the age of 58 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "All Sulfa Drugs" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: BNT162b2 (DOSE 1, SINGLE, Batch/Lot No: EN6206, Location of injection: Arm Left, Vaccine Administration Time: 09:00 AM), administration date: 17Mar2021, when the patient was 56-year-old, for Covid-19 immunisation; BNT162b2 (DOSE 2, SINGLE, Batch/Lot No: EP7534, Location of injection: Arm Left, Vaccine Administration Time: 10:00 AM), administration date: 07Apr2021, when the patient was 56-year-old, for Covid-19 immunisation; BNT162b2 (DOSE 3 (BOOSTER), SINGLE, Batch/Lot No: FO8448, Location of injection: Arm Left, Vaccine Administration Time: 06:00 PM), administration date: 13Oct2021, when the patient was 56-year-old, for Covid-19 immunisation; BNT162b2 (DOSE 4 (BOOSTER), SINGLE, Batch/Lot No: FM9992, Location of injection: Arm Left, Vaccine Administration Time: 03:00 PM), administration date: 15Apr2022, when the patient was 57-year-old, for Covid-19 immunisation; BNT162b2 (DOSE 5 (BOOSTER), SINGLE, Batch/Lot No: GJ2524, Location of injection: Arm Left, Vaccine Administration Time: 09:00 AM), administration date: 09Sep2022, when the patient was 57-year-old, for COVID-19 immunisation. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 16Dec2023, outcome "recovering" and all described as "COVID 19 Treatment". The event "covid 19 treatment" required physician office visit. The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (Dec2023) positive. Therapeutic measures were taken as a result of vaccination failure, covid-19 as Paxlovid from 17Dec2023 to 22Dec2023. Clinical course: Very mild symptoms experienced on 16Dec. Husband was exposed to Covid at work. He was under treatment 2 days prior to patient's positive test. 17Dec woke up mild aches. Had slightly sore throat and headache the evening of 16Dec and made an appointment at the Urgent Care for early 17Dec. Low grade fever and overall fatigue. Was prescribed Paxlovid. Began taking it the evening of 17Dec. On 18Dec, felt like she had a slightly stuffy nose on one side. All other symptoms were gone and she felt good.
Age: 72.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Drug ineffective, Interchange of vaccine products, SARS-CoV-2 test
Clinical narrative: Treatment of COVID-19; Treatment of COVID-19; Dose 7: Moderna/Dose 6: Pfizer; This is a spontaneous report received from a Consumer or other non HCP.  A 73-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 25Apr2023 at 12:00 as dose 6 (booster), single (Batch/Lot number: unknown) at the age of 72 years, in right arm for covid-19 immunisation; elasomeran (COVID-19 VACCINE MODERNA), on 30Oct2023 at 12:00 as dose 7 (booster), single), in right arm for covid-19 immunisation; COVID-19 vaccine (COVID-19 VACCINE), as dose 1, single), as dose 2, single), as dose 3 (booster), single), as dose 4 (booster), single) and as dose 5 (booster), single) for covid-19 immunisation. The patient's relevant medical history included: "Benign prostatic hyperplasia (BPH)" (unspecified if ongoing); "enlarged prostate" (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Codeine based pain medications, reaction(s): "allergies: Codeine". The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 30Oct2023, outcome "recovered", described as "Dose 7: Moderna/Dose 6: Pfizer"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Dec2023, outcome "recovered" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: negative, notes: Tested negative again after 6 days then again tested negative after 48 hours. Therapeutic measures were taken as a result of drug ineffective, covid-19 as Paxlovid treatment from 11Dec2023 to 16Dec2023.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 will be requested and submitted if and when received.
Age: 36.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Drug ineffective, SARS-CoV-2 test
Clinical narrative: Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a Consumer or other non HCP from product quality group.  A 38-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 14Oct2022 as dose 4 (booster), single (Lot number: GH9702) at the age of 36 years, in left arm for covid-19 immunisation; COVID-19 vaccine (COVID-19 VACCINE), as dose 1, single), as dose 2, single) and as dose 3 (booster), single) for covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Dec2023, outcome "recovered" (Dec2023) and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (Dec2023) Negative, notes: completed the full dosing schedule of the product, and after completing tested negative for 3 days. Therapeutic measures were taken as a result of drug ineffective, covid-19 which included Paxlovid from 18Dec2023 to 23Dec2023. Clinical course: The patient had no known allergies.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test, Vaccination failure
Clinical narrative: Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a Consumer or other non HCP.  A 42-year-old female patient (not pregnant) received BNT162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), on 08Nov2023 at 18:00 as dose 1, single (Batch/Lot number: unknown) at the age of 42 years, in left arm for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (DOSE 1, MANUFACTURER UNKNOWN), for COVID-19 immunization; Covid-19 vaccine (DOSE 2, MANUFACTURER UNKNOWN), for COVID-19 immunization; Covid-19 vaccine (DOSE 3 (BOOSTER), MANUFACTURER UNKNOWN), for COVID-19 immunization. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset Dec2023, outcome "unknown" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Negative. Therapeutic measures were taken as a result of vaccination failure, covid-19 which included paxlovid from 17Dec2023 to 23Dec2023. Clinical course: Known allergies: No.  The information on the batch/lot number for BNT162b2 omi xbb.1.5 will be requested and submitted if and when received.
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Vaccination failure
Clinical narrative: Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a Consumer or other non HCP.  A 75-year-old male patient received BNT162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), on 11Oct2023 at 14:30 as dose 1, single (Batch/Lot number: unknown), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Low back pain" (unspecified if ongoing); "Known allergies: Tetracycline" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (DOSE 1; MANUFACTURER UNKNOWN), for COVID-19 immunisation; Covid-19 vaccine (DOSE 2; MANUFACTURER UNKNOWN), for COVID-19 immunisation; Covid-19 vaccine (DOSE 3 (BOOSTER); MANUFACTURER UNKNOWN), for COVID-19 immunisation; Covid-19 vaccine (DOSE 4 (BOOSTER); MANUFACTURER UNKNOWN), for COVID-19 immunisation; Covid-19 vaccine (DOSE 5 (BOOSTER); MANUFACTURER UNKNOWN), for COVID-19 immunisation. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset Dec2023, outcome "unknown" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of vaccination failure, covid-19 with Paxlovid from 14Dec2023 to 19Dec2023.  No follow-up attempts are possible. Batch/lot number is not provided, and it cannot be obtained.
Age: 67.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Drug ineffective, SARS-CoV-2 test
Clinical narrative: COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a Consumer or other non HCP.  A 68-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 29Aug2023 as dose 6 (booster), single (Lot number: 0928) at the age of 67 years for covid-19 immunisation; COVID-19 vaccine (COVID-19 VACCINE), as dose 1, single), as dose 2, single), as dose 3 (booster), single), as dose 4 (booster), single) and as dose 5 (booster), single) for covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Dec2023, outcome "recovered" (Dec2023) and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (Dec2023) Negative. Therapeutic measures were taken as a result of drug ineffective, covid-19 with paxlovid from 16Dec2023 to 21Dec2023. Clinical course: Patient had no known allergies and Other medical history.
Age: 61.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Drug ineffective
Clinical narrative: COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from an Other HCP.  A 62-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 25Nov2022 as dose 5 (booster), single (Lot number: GL0446) at the age of 61 years, in right arm for covid-19 immunisation; COVID-19 vaccine (COVID-19 VACCINE), as dose 1, single), as dose 2, single), as dose 3 (booster), single) and as dose 4 (booster), single) for covid-19 immunisation. The patient's relevant medical history included: "Asthma" (unspecified if ongoing); "HTN" (unspecified if ongoing); "Pre-diabetes" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Dec2023, outcome "unknown" and all described as "COVID 19 Treatment". Therapeutic measures (Paxlovid treatment start date: 21Dec2023, stop date: 25Dec2023) were taken as a result of drug ineffective, covid-19. Clinical course: Patient had known allergies.  No follow-up attempts are possible.; Sender's Comments: Based on the information currently available, a lack of efficacy with bnt162b2 vaccine in this patient cannot be completely excluded.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test, Vaccination failure
Clinical narrative: initial COVID infection; initial COVID infection; This is a spontaneous report received from a Consumer or other non HCP.  A female patient in her 50's (not pregnant) received BNT162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), on 18Oct2023 as dose 1, single at the age of 56 years, in left arm for covid-19 immunisation. The patient had no relevant medical history. The patient had no known allergies. The patient's concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (DOSE 1; MANUFACTURER UNKNOWN), for COVID-19 immunization; Covid-19 vaccine (DOSE 2; MANUFACTURER UNKNOWN), for COVID-19 immunization; Covid-19 vaccine (DOSE 3 (BOOSTER); MANUFACTURER UNKNOWN), for COVID-19 immunization; Covid-19 vaccine (DOSE 4 (BOOSTER); MANUFACTURER UNKNOWN), for COVID-19 immunization. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 2023, outcome "recovered" (24Dec2023) and all described as "initial COVID infection". The clinical course was reported as follows: The patient had tested negative for 4 days after initial COVID infection starting on 24Dec2023 to 27Dec2023. The patient was given nirmatrelvir, ritonavir (PAXLOVID) as treatment of COVID-19 starting on 19Dec2023 until 24Dec2023. It was additionally reported that cetirizine hydrochloride (ZYRTEC) was started on 01Dec2023 until 28Dec2023. The patient underwent the following laboratory tests and procedures as aforementioned. Therapeutic measures were taken as a result of vaccination failure, covid-19.  No follow-up attempts are possible.
Age: 61.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Drug ineffective
Clinical narrative: COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from an Other HCP from product quality group.  A 63-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 21Dec2021 as dose 3 (booster), single (Lot number: 33036BD) at the age of 61 years for covid-19 immunisation; COVID-19 vaccine (COVID-19 VACCINE), as dose 1, single) and as dose 2, single) for covid-19 immunisation. The patient's relevant medical history included: "Allergies: Penicillin" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Dec2023, outcome "unknown" and all described as "COVID 19 Treatment". Therapeutic measures were taken as a result of drug ineffective, covid-19 with paxlovid from 19Dec2023  to 24Dec2023.  No follow-up attempts are possible.; Sender's Comments: The efficacy of a drug varies from patient to patient and can be affected by different factors; however, a contributory role of the suspect product BNT162b2 to the reported drug ineffective with COVID infection cannot be excluded.
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test, Vaccination failure
Clinical narrative: COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a Consumer or other non HCP.  A 67-year-old male patient received BNT162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), on 09Nov2023 as dose 1, single (Batch/Lot number: unknown) at the age of 67 years, in left arm for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (DOSE 1; MANUFACTURER UNKNOWN), for Covid-19 Immunization; Covid-19 vaccine (DOSE 2; MANUFACTURER UNKNOWN), for Covid-19 Immunization; Covid-19 vaccine (DOSE 3 (BOOSTER); MANUFACTURER UNKNOWN), for Covid-19 Immunization. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset Dec2023, outcome "recovered" (Dec2023) and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (21Dec2023) Negative; (22Dec2023) Negative. Therapeutic measures were taken as a result of vaccination failure, covid-19 with Paxlovid from 16Dec2023 to 20Dec2023. Clinical course: Patient had no known allergies.  No follow-up attempts are possible. Batch/lot number is not provided, and it cannot be obtained.
Age: 72.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Drug ineffective, SARS-CoV-2 test
Clinical narrative: COVID 19; COVID 19; This is a spontaneous report received from a Consumer or other non HCP.  A 72-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 23Aug2023 at 14:45 as dose 6 (booster), single (Batch/Lot number: unknown) at the age of 72 years, in left arm for covid-19 immunisation; COVID-19 vaccine (COVID-19 VACCINE), as dose 1, single), as dose 2, single), as dose 3 (booster), single), as dose 4 (booster), single) and as dose 5 (booster), single) for covid-19 immunisation. The patient's relevant medical history included: "known allergies: penicillin" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Dec2023, outcome "recovered" and all described as "COVID 19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (Dec2023) Negative; (Dec2023) Negative, notes: 48 hours apart. Therapeutic measures were taken as a result of drug ineffective, covid-19. The patient received PAXLOVID as covid-19 treatment from 17Dec2023 to 22Dec2023.   The lot number for BNT162b2, BNT162b2 omi ba.4-5, was not provided and will be requested during follow up.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300457544 Same reporter and patient; different drug and event;
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test, Vaccination failure
Clinical narrative: COVID-19; COVID-19; This is a spontaneous report received from a Physician.  An 81-year-old male patient received BNT162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), on 15Oct2023 at 15:00 as dose 1, single (Batch/Lot number: unknown) at the age of 81 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Gout" (unspecified if ongoing); "Allergies: latex and bananas" (unspecified if ongoing); "Allergies: latex and bananas" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: comirnaty (DOSE 1; administered in left arm at 10:00 AM), administration date: 04Jan2021, when the patient was 78-year-old, for Covid-19 Immunization; comirnaty (DOSE 2; administered in left arm at 10:00 AM), administration date: 25Jan2021, when the patient was 78-year-old, for Covid-19 Immunization; comirnaty (DOSE 4 (BOOSTER); administered in left arm at 03:00 PM), administration date: 13Sep2022, when the patient was 80-year-old, for Covid-19 Immunization; Comirnaty (DOSE 3 (BOOSTER); administered in left arm at 03:00 PM), for Covid-19 Immunization (reported as: 17Sep2022). The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 2023, outcome "recovered" (24Dec2023) and all described as "COVID-19". The clinical course was reported as follows: The patient had negative test 2 days after the last dose of nirmatrelvir, ritonavir (PAXLOVID) on 24Dec2023. The patient was given nirmatrelvir, ritonavir as treatment of COVID-19 starting on 18Dec2023 until 22Dec2023. The patient underwent the following laboratory tests and procedures as aforementioned. Therapeutic measures were taken as a result of vaccination failure, covid-19.  The information on the batch/lot number for BNT162b2 omi xbb.1.5 will be requested and submitted if and when received.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test, Vaccination failure
Clinical narrative: COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a Consumer or other non HCP.  A 63-year-old female patient (not pregnant) received BNT162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), on 23Sep2023 at 11:45 as dose 1, single (Batch/Lot number: unknown) at the age of 63 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Hypothyroid" (unspecified if ongoing); "known allergies: Latex sensitive" (unspecified if ongoing); "known allergies: allergic to cantaloupe" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 2023, outcome "unknown" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: on day 10; Negative, notes: on days 4-9; Negative, notes: on days 4-9; Negative, notes: on days 4-9. Therapeutic measures were taken as a result of vaccination failure, covid-19.   The information on the batch/lot number for BNT162b2 omi xbb.1.5 will be requested and submitted if and when received.
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Vaccination failure
Clinical narrative: COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a Consumer or other non HCP.  A 65-year-old male patient received BNT162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), on 01Nov2023 at 16:45 as dose 1, single (Batch/Lot number: unknown), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Asthma" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (DOSE 1; MANUFACTURER UNKNOWN), for COVID-19 Immunization; Covid-19 vaccine (DOSE 2; MANUFACTURER UNKNOWN), for COVID-19 Immunization; Covid-19 vaccine (DOSE 3; MANUFACTURER UNKNOWN), for COVID-19 Immunization; Covid-19 vaccine (DOSE 4; MANUFACTURER UNKNOWN), for COVID-19 Immunization; Covid-19 vaccine (DOSE 5; MANUFACTURER UNKNOWN), for COVID-19 Immunization; Covid-19 vaccine (DOSE 6; MANUFACTURER UNKNOWN), for COVID-19 Immunization. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset Dec2023, outcome "unknown" and all described as "COVID 19 Treatment". Therapeutic measures were taken as a result of vaccination failure, covid-19.  Clinical course: Paxlovid was the treatment for COVID-19. Treatment start date: 18Dec2023. Treatment stop date: 22Dec2023  The information on the batch/lot number for BNT162b2 omi xbb.1.5 will be requested and submitted if and when received.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Vaccination failure
Clinical narrative: COVID 19; COVID 19; This is a spontaneous report received from a Consumer or other non HCP.  A 32-year-old female patient (not pregnant) received BNT162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), in Oct2023 as dose 1, single (Batch/Lot number: unknown) at the age of 32 years for covid-19 immunisation. The patient's relevant medical history included: "Covid", start date: Dec2019 (unspecified if ongoing); "Psoriatic Arthritis" (unspecified if ongoing), notes: Diagnosed after first ever covid infection. The patient's concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (DOSE 4; MANUFACTURER UNKNOWN), for COVID-19 immunization; Covid-19 vaccine (DOSE 3; MANUFACTURER UNKNOWN), for COVID-19 immunization; Covid-19 vaccine (DOSE 2; MANUFACTURER UNKNOWN), for COVID-19 immunization; Covid-19 vaccine (DOSE 1; MANUFACTURER UNKNOWN), for COVID-19 immunization. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset Dec2023, outcome "unknown" and all described as "COVID 19". Therapeutic measures were taken as a result of vaccination failure, covid-19. The patient received PAXLOVID as covid-19 treatment from 19Dec2023 to 24Dec2023.  The lot number for BNT162b2 omi xbb.1.5, was not provided and will be requested during follow up.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202400000305 Same patient, different drug and event;
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective
Clinical narrative: COVID-19; COVID-19; This is a spontaneous report received from a Consumer or other non HCP from product quality group.  A 74-year-old female patient (not pregnant) received BNT162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), on 19Oct2023 at 17:00 as dose 1, single (Lot number: HG4677) at the age of 74 years, in left arm for COVID-19 immunisation. The patient's relevant medical history included: "MGUS" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: BNT162b2;BNT162b2 omi ba.4-5 (DOSE NUMBER UNKNOWN (BOOSTER), SINGLE, Vaccine administration time: 11:30 AM, Vaccine lot number: GH9694, Vaccine location: Left arm), administration date: 16Sep2022, when the patient was 73-year-old, for COVID-19 Immunization; COVID-19 vaccine (DOSE NUMBER UNKNOWN, SINGLE, UNKNOWN MANUFACTURER), for COVID-19 Immunization. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID-19". Therapeutic measures were taken as a result of drug ineffective, COVID-19.  No follow-up attempts are possible. Batch/lot number is not provided, and it cannot be obtained.
Age: 54.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Vaccination failure
Clinical narrative: Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a Consumer or other non HCP from product quality group.  A 54-year-old male patient received BNT162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), on 06Oct2023 as dose 1, single (Lot number: HG2649) at the age of 54 years, in right arm for covid-19 immunisation. The patient's relevant medical history included: "Acid reflux" (unspecified if ongoing); "high blood pressure" (unspecified if ongoing); "walnuts" (unspecified if ongoing); "Pecans" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: BNT162b2;BNT162b2 omi ba.4-5 (DOSE 5 (BOOSTER), SINGLE, Batch/Lot No: GJ3277, Location of injection: Arm Right), administration date: 08Oct2022, when the patient was 53-year-old, for Covid-19 immunization; BNT162b2 (DOSE 4 (BOOSTER), SINGLE, Batch/Lot No: FN9992, Location of injection: Arm Right), administration date: 23May2022, when the patient was 53-year-old, for Covid-19 immunization; BNT162b2 (DOSE 3 (BOOSTER), SINGLE, Batch/Lot No: FF2590, Location of injection: Arm Right), administration date: 15Oct2021, when the patient was 52-year-old, for covid-19 immunization; BNT162b2 (DOSE 2, SINGLE, Batch/Lot No: EN2021, Location of injection: Arm Right), administration date: 29Mar2021, when the patient was 52-year-old, for covid-19 immunization; BNT162b2 (DOSE 1, SINGLE, Batch/Lot No: EN6200, Location of injection: Arm Right), administration date: 05Mar2021, when the patient was 52-year-old, for covid-19 immunization. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of vaccination failure, covid-19. Patient received Paxlovid as COVID 19 Treatment, from 16Dec2023 till 21Dec2023.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective, Interchange of vaccine products
Clinical narrative: COVID 19 Treatment; COVID 19 Treatment; Dose 5:Pfizer;Dose 7/Dose 6/:Moderna; This is a spontaneous report received from a Consumer or other non HCP from product quality group.  A 74-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown), as dose 3 (booster), single (Batch/Lot number: unknown), as dose 4 (booster), single (Batch/Lot number: unknown) and on 18May2022 as dose 5 (booster), single (Lot number: PM9992) at the age of 72 years, in left arm for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), on 15May2023 as dose 6 (booster), single (Lot number: 7172D), in left arm and on 20Oct2023 as dose 7 (booster), single (Lot number: 1111), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Osteoporosis" (unspecified if ongoing). The patient had no known allergy. Concomitant medication(s) included: FAMOTIDINE, start date: Apr2022. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 15May2023, outcome "unknown", described as "Dose 5:Pfizer;Dose 7/Dose 6/:Moderna"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19 Treatment". Therapeutic measures were taken as a result of drug ineffective, covid-19 including Paxlovid from 20Dec2023 to 24Dec2023.  The information on the batch/lot number for BNT162b2 will be requested and submitted if and when received.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Vaccination failure
Clinical narrative: Patient was treated with PAXLOVID for COVID-19 treatment; Patient was treated with PAXLOVID for COVID-19 treatment; This is a spontaneous report received from a Consumer or other non HCP.  A 59-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 30Dec2022 as dose 4 (booster), single (Lot number: GJ6665) at the age of 58 years, in left arm for covid-19 immunisation; BNT162b2 (BNT162B2), on 08Mar2021 as dose 1, single (Lot number: EP6955), in left arm, on 08Apr2021 as dose 2, single (Lot number: EW0161), in left arm and on 20Nov2021 as dose 3 (booster), single (Lot number: FJ1611), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Generalised anxiety disorder" (unspecified if ongoing). Concomitant medication(s) included: PROGESTERONE, start date: 01Dec2021. Past drug history included: Amoxicillin, reaction(s): "Drug allergies: AMOXICILLIN"; Lexapro, start date: 01Jan2021. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 2023, outcome "unknown" and all described as "Patient was treated with PAXLOVID for COVID-19 treatment". Therapeutic measures were taken as a result of vaccination failure, covid-19.
Sex: U
Vaccine: RSV
Symptoms: Vaccination site bruising, Vaccination site discolouration, Vaccination site induration, Vaccination site pain, Vaccination site swelling
Clinical narrative: having very swollen/hard spot where vaccine was administered; having very swollen/hard spot where vaccine was administered; Very painful and Bruised; Very painful and Bruised; This is a spontaneous report received from a Consumer or other non HCP, Program ID.  A patient (age and gender not provided) received rsv vaccine prot.subunit pref 2v (RSV VACCINE PROT.SUBUNIT PREF 2V), on 13Dec2023 as dose number unknown, single (Batch/Lot number: unknown) for immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: VACCINATION SITE PAIN (non-serious), VACCINATION SITE BRUISING (non-serious) all with onset 18Dec2023, outcome "unknown" and all described as "Very painful and Bruised"; VACCINATION SITE MASS (non-serious), VACCINATION SITE SWELLING (non-serious) all with onset 18Dec2023, outcome "unknown" and all described as "having very swollen/hard spot where vaccine was administered". Additional information: the patient experienced very swollen/hard spot where vaccine was administered. Very painful and Bruised (black & Blue).  The information on the batch/lot number for rsv vaccine prot.subunit pref 2v, rsv vaccine prot.subunit pref 2v  will be requested and submitted if and when received.
Sex: U
Vaccine: COVID19
Symptoms: Therapeutic response unexpected
Clinical narrative: After my first booster shot I can now eat gluten and not get sick.; This is a spontaneous report received from a Consumer or other non HCP, Program ID.  A patient (age and gender not provided) received BNT162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Primary Immunization series complete; unknown manufacturer), for COVID-19 immunisation. The following information was reported: THERAPEUTIC RESPONSE UNEXPECTED (non-serious), outcome "unknown", described as "After my first booster shot I can now eat gluten and not get sick.". The events "after my first booster shot i can now eat gluten and not get sick." required physician office visit. Additional information: patient's doctors can't explain it.
Sex: U
Vaccine: COVID19
Symptoms: Nausea
Clinical narrative: nauseated; This is a spontaneous report received from a Consumer or other non HCP. Other Case identifier(s): 2023NVX-US-000001870 (Novavax).  A patient (age and gender not provided) received BNT162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported.The following information was reported: NAUSEA (non-serious), outcome "unknown", described as "nauseated". Additional information:It was reported the patient was nauseated for days afterwards. No follow-up attempts are possible. Batch/lot number is not provided, and it cannot be obtained.
Sex: M
Vaccine: COVID19
Symptoms: Influenza like illness, Interchange of vaccine products, Off label use
Clinical narrative: Off label use; Interchange of vaccine products; I lay flat for a day with flu-like symptoms and a headache; This is a spontaneous report received from a Consumer or other non HCP.  A 46-year-old male patient received BNT162b2 (BNT162B2), on 23Jun2021 as dose 2 (initial pfizer dose), single (Lot number: EW0217) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: COVID-19 vaccine astrazeneca (DOSE 1, SINGLE, Batch\lot number: ABW4330), administration date: 04May2021, for COVID-19 immunisation. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (non-serious) with onset 23Jun2021, outcome "recovered"; OFF LABEL USE (non-serious) with onset 23Jun2021, outcome "recovered"; INFLUENZA LIKE ILLNESS (non-serious), outcome "recovered", described as "I lay flat for a day with flu-like symptoms and a headache".  Additional information: The patient received Moderna as dose 3 (booster), single on 06Dec2021 (lot number: 3004954) for COVID-19 immunisation.
Sex: U
Vaccine: RSV
Symptoms: Vaccination site pruritus
Clinical narrative: A large, itchy area on the arm where the vaccine was given; This is a spontaneous report received from a Consumer or other non HCP, Program ID.  A patient (age and gender not provided) received rsv vaccine prot.subunit pref 2v (RSV VACCINE PROT.SUBUNIT PREF 2V), on 28Dec2023 as dose number unknown, single (Batch/Lot number: unknown), in arm for immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: VACCINATION SITE PRURITUS (non-serious), outcome "unknown", described as "A large, itchy area on the arm where the vaccine was given".  The information on the batch/lot number for rsv vaccine prot.subunit pref 2v will be requested and submitted if and when received.
Sex: F
Vaccine: PNC15, PPV
Symptoms: Abdominal discomfort, Asthenia, Hypersensitivity, Mobility decreased, Rash
Clinical narrative: caused her " break out", made her sick to her stomach, and took all of her energy away; took all of her energy away; The patient notes that she was in bed all day for two weeks straight after taking this vaccine; the patient experienced a really bad allergic reaction; This spontaneous report was received from consumer and refers to a 90-year-old female patient.   The patient's concurrent conditions included blood pressure high, and hypersensitivity. The patient's medical history included insomnia. Her Historical drugs included sulfa drugs, and aspirin and her historical vaccine was pneumococcal vaccine. Concomitant medications included diltiazem hydrochloride (CARDIZEN), escitalopram, losartan and omeprazole.   On an unknown date (also reported as few years ago), the patient started therapy with pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) injection,  (strength, dose description, lot #, expiry date, route of administration, and indication were not provided); pneumococcal 15v conj vaccine (crm197) (VAXNEUVANCE) injection,  (strength, dose description, lot #, expiry date, route of administration, and indication were not provided); and  pneumococcal 15v conj vaccine (VAXNEUVANCE SYRINGE (DEVICE)) injection,  (strength, dose description, lot #, expiry date, route of administration) for prophylaxis.  On an unspecified date, the patient experienced a really bad allergic reaction (Drug hypersensitivity) which caused her " break out", made her sick to her stomach (Abdominal discomfort), and took all of her energy away (Asthenia). The patient notes that she was in bed all day for two weeks straight after the vaccine(Bedridden). The outcome of the events were not reported.   The reporter considered the upset stomach, loss of energy and drug hypersensitivity related to pneumococcal 23v polysaccharide vaccine (PNEUMOVAX23) and pneumococcal 15v conj vaccine (crm197) (VAXNEUVANCE) but to bedridden was no reported.
Age: 36.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Drug ineffective
Clinical narrative: COVID-19; COVID-19; This is a spontaneous report received from a Consumer or other non HCP.  A 38-year-old male patient received BNT162b2 (BNT162B2), on 20Dec2021 at 12:00 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 36 years, in left arm for covid-19 immunisation; COVID-19 vaccine (COVID-19 VACCINE), as dose 1, single and as dose 2, single for covid-19 immunisation. The patient's relevant medical history included: "Type 1 Diabetes" (unspecified if ongoing). The patient had no known allergies. Concomitant medication(s) included: HUMALOG. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Dec2023, outcome "unknown" and all described as "COVID-19". Therapeutic measures were taken as a result of drug ineffective, covid-19. The patient received PAXLOVID as covid 19 treatment from 28Dec2023 to 01Jan2024.  The lot number for BNT162b2, was not provided and will be requested during follow up.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202400000006 Same patient, different product and event;
Age: 68.0
Sex: M
Vaccine: FLU4, VARZOS
Symptoms: Abdominal pain upper, Headache, Myalgia
Clinical narrative: Muscle pain, headache, stomach pain for 7 days.
Age: 28.0
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: No adverse events reported. On 1/4/24, pharmacist discovered that open box of vaccine in fridge was past BUD of 12/21/23. Pharmacist contacted Moderna and received a ticket and is awaiting lot assessment to determine product stability determination and instructions.
Age: 79.0
Sex: F
Vaccine: COVID19-2
Symptoms: Laboratory test, Limb injury, Loss of consciousness
Clinical narrative: Patient's husband came in the pharmacy on 1/3/24 to report an adverse reaction post vaccination. He said that his wife had received a covid vaccine in the morning of 12/19/23 . She suddenly lost consciousness that evening when she was at home and hurt her leg in the process. When she was rushed to ER, they were told after running several tests on her that the covid vaccine was the most likely culprit for her loss of consciousness. Patient is now doing well per husband, he just wants us to document incident in her profile.
Age: 81.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Wrong product administered
Clinical narrative: Resident received Spikevax Covid-19 updated 2023-2024 vaccine on 12/29/2023. Resident mistakenly received second Spikevax Covid-19 updated 2023-2024 vaccine (same dose, lot number, manufacturer) on 1/4/2024. Resident has demonstrated no adverse effects. No symptoms of distress noted.
Age: 61.0
Sex: F
Vaccine: FLU4
Symptoms: Arthralgia, Joint swelling
Clinical narrative: Pt. states she began experiencing pain and swelling in her joints 2 days after getting the vaccine.  She states these symptoms are persistent and have not improved as of today (1/4/24). States she has an appointment scheduled with her PCP but has not received any treatment yet.
Age: 39.0
Sex: M
Vaccine: RAB
Symptoms: Cold sweat, Diarrhoea, Malaise, Vaccination site erythema, Vaccination site pain
Clinical narrative: Feelings of malaise, diarrhea, clamy, arm tender and red at vaccine site. Donor stated around 5a.m. signs and symptoms started to occur. Spoke with the donor at 6:30 p.m. and the donor signs and symptoms has not changed.
Age: 52.0
Sex: F
Vaccine: VARZOS
Symptoms: Blister, Crying, Herpes zoster, Paraesthesia, Rash
Clinical narrative: 7 days after receiving the first dose of the Shingrix vaccine, I discovered a small rash on my right shoulder that was itchy and tingled.  Within a few hours, the rash had spread down the front of my chest.  Upon closer inspection, the rash included weeping blisters and the beginning of a crust forming around the rash.  I went to the walk in clinic of my primary care practice and they decided to treat me for shingles.  Before the vaccination, I did not have any symptoms of shingles at all, but I had chickenpox as a child and also have a long history of autoimmune diseases.
Age: 52.0
Sex: F
Vaccine: VARZOS
Symptoms: Rash pruritic, Scab
Clinical narrative: 7 days after receiving the first dose of the Shingrix vaccine, I discovered a small rash on my right shoulder that was itchy and tingled.  Within a few hours, the rash had spread down the front of my chest.  Upon closer inspection, the rash included weeping blisters and the beginning of a crust forming around the rash.  I went to the walk in clinic of my primary care practice and they decided to treat me for shingles.  Before the vaccination, I did not have any symptoms of shingles at all, but I had chickenpox as a child and also have a long history of autoimmune diseases.
Age: 11.0
Sex: F
Vaccine: TDAP
Symptoms: Peripheral swelling, Pruritus
Clinical narrative: Moderate swelling  and itching  to Lt arm after receiving vaccine.  Itching resolved with ice. Swelling is aggravated by pressure.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: The patient receive a dose of vaccine after beyond use date of 12-29-23.
Age: 34.0
Sex: F
Vaccine: RSV
Symptoms: Exposure during pregnancy, Wrong product administered
Clinical narrative: Patient Pregnant and received Arexvy instead of Abryso.
Age: 39.0
Sex: F
Vaccine: COVID19-2
Symptoms: Asthenia, Diarrhoea, Fatigue, Feeding disorder, Nausea
Clinical narrative: Have had nausea, frequent explosive diarrhea, and mostly unable to eat.  I have also been tired, weak, achy
Age: 39.0
Sex: F
Vaccine: COVID19-2
Symptoms: Pain
Clinical narrative: Have had nausea, frequent explosive diarrhea, and mostly unable to eat.  I have also been tired, weak, achy
Age: 54.0
Sex: F
Vaccine: RSV
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: Patient received vaccine under 60 years old. Pharmacist re-educated
Age: 73.0
Sex: F
Vaccine: RSV
Symptoms: Seizure
Clinical narrative: Sitting on the sofa with her husband and he saw her have a "full blown seizure."  They did not call 911 or go to the hospital or go to the dr.  She is was fine after the seizure and did not seek medical attention.  She did tell her doctor after the fact about the seizure and got a rx for dilantin 100mg  three times daily.
Age: 32.0
Sex: F
Vaccine: FLU4, VARZOS
Symptoms: Unevaluable event
Clinical narrative: Administered a Shingrix (immunocompromised) vaccine to a patient that self-attested that she was immunocompromised and eligible to receive the Shingrix vaccine. Later found out that she was intellectually disabled and not able to consent to the vaccine although she signed a consent form.
Age: 0.17
Sex: F
Vaccine: DTPPVHBHPB
Symptoms: Allergy test, Eczema, Food allergy, Milk allergy
Clinical narrative: Chronic Eczema all over her body. Peanut, Cows Milk, and Egg allergy. She had lactose in formula prior to vaccine and she was completely fine.
Age: 80.0
Sex: F
Vaccine: VARZOS
Symptoms: Palpitations
Clinical narrative: Patient called the day after vaccine and complained of heart palpitations starting evening of 1/3/24 into morning of 1/4/24
Age: 15.0
Sex: F
Vaccine: COVID19
Symptoms: Antinuclear antibody increased, Blood test, Costochondritis, Inflammation, Magnetic resonance imaging
Clinical narrative: Inflammatory issues started to happen, Knees,  toes, hands and chest/ribs (costochondritis), ANA only thing elevated.  Has been off and on for 2 years now, previously perfectly healthy. Never had covid prior to symptoms starting after 3rd dose of vaccine.
Age: 15.0
Sex: F
Vaccine: COVID19
Symptoms: Peripheral swelling, Rash
Clinical narrative: Inflammatory issues started to happen, Knees,  toes, hands and chest/ribs (costochondritis), ANA only thing elevated.  Has been off and on for 2 years now, previously perfectly healthy. Never had covid prior to symptoms starting after 3rd dose of vaccine.
Age: 85.0
Sex: M
Vaccine: COVID19-2
Symptoms: Blood test normal, Computerised tomogram normal, Condition aggravated, Deafness unilateral, Dizziness
Clinical narrative: One week after vaccine had dizzy spell followed by almost complete loss of hearing in right (good) ear..  Dizziness gone by next day.  Loss of hearing being treated with so far not much success
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site swelling, Mobility decreased
Clinical narrative: VISIBLY SWELLING OF THE INJECTION SITE AND UPPER ARM (DELTOID MUSCLE AREA) AND BEING NOT ABLE TO MOVE. PT DIDN'T TAKE ANY TREATMENT BUT SHE'S ON HYDROCODONE/APAP 7.5/325 MG FOR HER OTHER PAIN.
Age: 12.0
Sex: M
Vaccine: COVID19
Symptoms: Underdose
Clinical narrative: NOT AN ADVERSE EVENT! Patient was given lower than authorized dose of Pfizer vaccine for age 5-11 years old (10 micrograms) instead of the 30 micrograms for age 12 years and up.
Age: 69.0
Sex: M
Vaccine: COVID19, FLU4
Symptoms: Amnesia
Clinical narrative: Patient received the vaccine at 11:30 am 11/23/23. The patient states he went to work, picked up his badge and radio, and was working. He does not remember how he got home that day. He was home with his work supplies but has no recollection of driving home that night.  He went to the emergency room at 8pm that night upon realizing what had happened.
Age: 85.0
Sex: F
Vaccine: VARZOS
Symptoms: Migraine, Pain, Pain in extremity, Pyrexia, Rash
Clinical narrative: patient reported localized rash,  fever for 2 days, migraine for 5 days and persistent sore arm